<DOC>
	<DOCNO>NCT00570999</DOCNO>
	<brief_summary>This double blind , placebo control clinical trial , patient advance form blood cancer treat haploidentical allogeneic peripheral blood progenitor cell ( PBPC ) transplant randomise receive either placebo keratinocyte growth factor ( Palifermin Kepivance® ) . The function Kepivance® stimulate growth epithelial cell . This drug also suggest ability help improve reconstitution , development , immune system transplantation . The hypothesis patient T-cell dependent humoral immune response recall antigen ( PrevenarTM ) high palifermin treat patient placebo control group</brief_summary>
	<brief_title>Palifermin After Haploidentical PBSCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Recipient : Chemosensitive low/high grade BNHL TNHL , Multiple Myeloma ( MM ) partial complete remission ALL AML , secondary AML biphenotypic acute leukemia complete remission ( CR1 CR2 ) PR ( ≤20 % blast BM ) , Myelodysplastic syndrome ( MDS ) CML chronic accelerate phase Osteomyelofibrosis ( OMF ) Hodgkin lymphoma ( HD ) partial complete remission Age ≥18 year , ≤ 65 year ECOG status ≤2 Prior treatment 3 le different chemotherapy regimen ( cycle ) ; prior local radiotherapy allow except radiation involve thymus Adequate pulmonary function Left ventricular ejection fraction ( LVEF ) &gt; 30 % Haploidentical relate donor Failure find matched relate match unrelated donor urgently require transplantation Planned condition regimen per Aversa Würzburg protocol Women must postmenopausal , sterile use effective contraception negative pregnancy test study entry ( βHCG neg ) Signed informed consent Donor : Healthy family member Selection base type HLAA , B , C , DR locus . Donor must least genotypically HLAA , B , C , DR haploidentical patient , must differ 23 HLA allele ( ) unshared haplotype Donors must capable undergoing leukapheresis , adequate venous access , willing undergo insertion central venous catheter leukapheresis via peripheral vein inadequate . Donors must agree 2nd donation PBPCs case insufficient CD34+ cell collection patient fail demonstrate sustain engraftment Signed inform consent Recipient : History concurrent cancer ( &lt; 5 year ago ) name inclusion criterion Primary chemorefractory disease CML blast crisis MM minor response previous treatment Prior treatment palifermin , keratinocyte growth factor Documented hypersensitivity palifermin , E. coliderived protein , component product Documented hypersensitivity Prevenar vaccine component Prior allogeneic tandem PBPC transplantation ( 1 previous autologous transplantation Prior total body irradiation Post thymectomy Major anticipate illness organ failure incompatible survival PBPC transplantation Active chronic skin disease require therapy Active inflammatory bowel disease require therapy Active uncontrolled infection Seropositive HIV Pregnancy breastfeed Active invasive fungal tissue infection ( EORTC criterion ) 30 day less since receive investigational product device another clinical trial Concurrent enrolment another trial permit unless purpose longterm followup/survival data , observational Chronic pancreatitis history acute pancreatitis within 1 year prior transplant Psychiatric disorder associate incompliance Myocardial infarction le 3 month pre enrolment EF &lt; 30 % measure echocardiography/laevoventriculography Infusion retrovirally transduce cell permit . Planned intravenous application immunoglobulin contraindicate throughout study period . Donor lymphocyte infusion allow . Donor : A positive HIV HTLV1 test evidence active/persistent viral hepatitis infection . Evidence active infection Any medical condition ( i.e . insulindependent diabetes , cardiovascular disorder , chronic inflammatory disease ) pose health risk peripheral blood stem cell harvest Hematopoietic marrow function relate disease interfere collection sufficient number normal progenitor cell Pregnancy breastfeed Any malignancy besides basal cell epithelioma cure malignancy &lt; 5 year ago Psychiatric disorder associate incompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Peripheral blood stem cell transplantation</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
	<keyword>Prevenar</keyword>
	<keyword>Placebo</keyword>
</DOC>